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RESUMEN
Introducción: La Enfermedad por coronavirus 2019 (COVID-19) causada por el virus SARS-CoV-2, con 
característica de infectar el tracto respiratorio causando un síndrome respiratorio agudo como paso ini-
cial para ingresar a la célula huésped el virus usa los receptores ACE II y la proteína transmembrana 
TMPRSS2 para causar la infección, Por lo que se ha descrito diferentes tipos de fármacos para realizar su 
inhibición en la adhesión del paso inicial.
Metodología: Revisión no sistemática de artículos con la ayuda de palabras clave preestablecidas.
Resultados: En esta revisión presentaremos fármacos que inhiben este tipo de receptor, por lo tanto, 
estos medicamentos podrían considerarse candidatos potenciales para mitigar la propagación del SARS-
CoV-2.
Palabras Clave: TMPRSS2; ACE II; COVID-19; 2019-nCoV; Coronaviridae.
ABSTRACT
Introduction: Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus with characteristic 
of infecting the respiratory tract, causing severe acute respiratory syndrome. The virus uses the ACE II 
receptors and the transmembrane protein TMPRSS2 initial step to enter the host cell, this contribution 
described different types of drug, to perform its inhibition in initial step adhesion.
Methodology: Non-systematic review of articles with the help of preset keywords
Results: In this review we will present drugs that inhibitors of this type of receptor therefore these drugs 
could be considered potential candidates to mitigate the spread of SARS-CoV-2.
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INTRODUCTION
The 2019 coronavirus disease epidemic (COVID-19) caused 
by the new SARS-CoV-2 virus has led to the spread of se-
rious respiratory lung disease worldwide. According to 
Baltimore, this new virus belonging to the Coronaviridae 
family classified in group III, defined as a single-stranded 
RNA virus with a positive sense. It presents a generally 
large genome which could present mutations over time(1,2). 
Several viruses in this family have been considered as in-
fectious agents causing common colds, that is way they are 
in constant circulation in the human population. However, 
different viruses belonging to this family have appeared 
that have caused serious problems infecting thousands of 
people, such as (SARS-CoV) associated with Severe Acute 
Respiratory Syndrome in 2003, and (MERS-CoV)(3) associat-
ed with Middle East Respiratory Syndrome in 2002.
Currently (July, 16th 2020) the new coronavirus has spread 
in 188 countries which has infected 13,744,743 people caus-
ing 588,383 deaths(4) until today. The spread of this virus 
has increased significantly due to the type of transmission 
which has not yet reached a clear consensus; It has been 
said that this kind of virus has different forms of transmis-
sion: from animals to humans; from humans to animals; 
and from humans to humans; through contact; and respira-
tory droplets(5) . Furthermore, it is not certain that the virus 
is transmitted by air, however, the COVID-19 virus can be 
spread indirectly by contact with surfaces in its immediate 
environment or with objects that have been used by some-
one infected, highlighting that the viral particle can be stay 
on these surfaces for an estimated time(6). 
Based on the above, the specific route of transmission of 
natural reservoirs to humans continues in contradictions. 
The most accurate evidence believed so far is that pango-
lins are responsible for providing this transmission to hu-
mans. This shows us that the receptor-binding domain of 
the S protein of pangolin-CoV is almost similar to SARS-
CoV-2(7). Different studies have shown that the angioten-
sin-converting enzyme 2 (ACE II) plays an important role 
as a receptor for SARS-CoV-2 in the binding of eukaryotic 
animal cells in the vicinity to infect, however, it has been 
intensified that the serine TMPRSS2 protease as a crucial 
adjuvant (cofactor) for the binding of this virus peak pro-
tein(8) converting these receptors as potential candidates for 
the development of white molecules that prevent the entry 
of the virus and thus counteract the pandemic caused by 
SARS-CoV-2. Therefore, this article identifies some recep-
tor inhibitor molecules that contribute to virus adhesion in 
human host cells. 
MATERIAL AND METHODS 
A non-systematic review of clinical cases, original and re-
view articles was carried out in indexed databases such 
as PubMed; ScienceDirect; Springer; and OVID in first, 
and second language from 2005-2020 mainly. For this re-
search paper, The MeSH terms used for the article search 
and selection process were TMPRSS2, ACE II, COVID-19, 
2019-nCoV, New treatment strategies, SARS-CoV-2, and 
Coronaviridae. Only the articles that had the MeSH terms 
were selected. This search strategy consisted of combining 
the MeSH terms as exclusion or inclusion criteria to make 
the search process more efficiently.
RESULTS AND DISCUSSION 
The TMPRSS2 receptor has been studied as one of the main 
receptors for target cells with the assistance of ACE II. For 
this reason, different drugs that inhibit these two recep-
tors have been tested, in order to counteract the adherence 
SARS-Cov-2 in human host cells.
Camostat mesilate and Nafamostat
Nowadays, Camostat has a wide range of uses. That is why 
this drug could be considered as one of the most promis-
ing candidates for the treatment of respiratory infections 
caused by SARS-Cov-2 today. Since this drug achieves the 
blocking of serine protease enzymes. In fact, this inhibitor 
was approved in Japan as a treatment of chronic pancre-
atitis, and postoperative reflux esophagitis (9). According to 
studies, and clinical trials, Camostat can block the entry of 
the SARS-CoV2 virus inside the target cell. This has been 
demonstrated by in vitro cell test where this drug obstructs 
the adherence of the SARS-CoV virus, and the SARS-CoV-2 
glycoprotein, if it is provided at a concentration of 10 μM(10). 
On the other hand, different research suggests Nafamostat, 
a serine protease inhibitor, as another candidate drug for 
combating Covid-19, since it is known that Nafamostat 
blocks MERS-CoV virus infection in vitro by inhabiting 
the activity of TMPRSS2 thus achieving a 100-fold reduc-
tion in viral entry at a concentration as low as 1 nM. This 
means that it is more effective than Camostat. That said, 
Nafasmostat could contribute to blocking the entry of the 
new coronavirus into cells close to infecting it. This is how 
Nafamostat becomes another interesting drug for studies 
against SARS-COV-2(11).
Bromhexine Chlorhydrate 
It is a mucolytic agent used in the treatment of respiratory 
disorders associated with excessive and viscous mucus. It 
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was previously used for the treatment of influenza virus, 
and coronavirus infections as an inhibitor of TMPRSS2. 
Bromhexim contributed significantly to the inhibition of 
trypsin-like proteases, expressed in the human respiratory 
tract of influenza, such as the SARS-CoV and MERS virus-
es(12).
According to the reports presented by Shen et al(13), this 
drug could be used for treatment of infections caused by 
viruses of the coronaviridae family that cause severe re-
spiratory infections. They suggest that these drugs can be 
used to treat patients who are asymptomatic of covid-19, in 
order to prevent the virus spread, which would cause mul-
tiple effects in the most vulnerable population who would 
suffer an infection by 2019- nCoV.
Morpholine phosphorodiamidate oligomers linked to 
peptide
Morpholine phosphorodiamidate oligomers (PPMO) are 
synthetic antisense molecules. These molecules target the 
genetic code within the virus. they avoid the virus repro-
duction ability since they can interfere with gene expres-
sion by sterically blocking complementary RNAs(14). This 
synthetic compound interferes in the correct splicing in 
pre-mRNA of TMPRSS2 receptor, causing the mature 
mRNA production without the presence of exon 5. This 
leads to the incorrect genetic expression of the receptor. 
That is why these synthetic agents resemble single-strand-
ed DNA, and can easily enter the target cell to change the 
pre-mRNA splicing pattern. 
There are in vitro results that show us this molecule could 
contribute to the drastic reduction of SARS-CoV-2 in cell 
cultures. In others words, this molecule can reduce the con-
tagion rate in a range of time of 16, 24, and 48 hours after 
the cell cultures were exposed to the virus(16).
Polyamide
Polyamide is a type of polymer that contains amide-type 
bonds. Many researches have used this polymer to develop 
different therapeutic treatment. Also, this polymer has been 
used to coat medical devices as it functions as an antimicro-
bial agent in the clinic devices(17).In this research, polyam-
ide is suggested as another candidate drug to counteract 
respiratory infections caused by SARS-CoV-2 since its com-
pounds moderately block the TMPRSS2 receptor; There-
fore, this drug may moderately contribute to the non-ad-
herence of some viruses that use this receptor as a route 
of entry to host cells, such as the current SARS-CoV-2(18-19).
Rubitecan, Lorazepam, Zinc15 and Ascorbic Acid
Rubitecan is an enantiomer 20 (S) enantiomer 9-nitrocamp-
tothecin (9-NC). Its main function is to act as an inhibi-
tor of tumor activity, presenting a blocking molecule that 
prevents cell replication. On the other hand, lorazepam is 
a drug from the benzodiazepine family, which is given as 
a treatment for short-term insomnia, hypnotics, and mus-
cle spasms(20). These target molecules have been tested in 
silico by docking and molecular dynamics. The test result 
showed a high binding affinity between these drugs (li-
gands) and the TMPRSS2 receptor (target molecule) Also, 
this test result could highlight a relatively low energy value 
that showed us that these molecules could be candidates to 
counteract the entry of the virus into the cell. 
Likewise, the Zinc15 molecule has been studied as a poten-
tial inhibitor of the entry pathway through the receptor of 
the transmembrane protein TMPRSS2, which in molecular 
coupling has a very high affinity for this protein(21). Also, 
Ascorbic acid or vitamin C can work as a weak antihista-
mine agent, which in turn contributes to the symptoms of 
lower respiratory infections. The inhibition of ACE II recep-
tor in turn contributes to the non-expression of TMPRSS2, 
thus helping to mitigate flu symptoms and, in turn, vitamin 
C could be considered as another alternative to treat criti-
cally ill patients with covid19(22).
The aforementioned information highlights different candi-
date molecules that may be targets for inhibiting the spread 
of 2019-nCoV infection. The Table 1 shows us another sum-
mary about the characteristics of these drugs that could be 
successful to reduce SARS-CoV-2 infection.
CONCLUSION
All the drugs mentioned in this review could contribute 
to the aim of achieving the actions that prevent the entry 
of the SARS-CoV-2 virus by serine protease. Although the 
mechanisms of action and efficacy of these drugs require 
more rigorous studies to have full certain of their results 
in human beings, they cannot be ruled out as possible can-
didates, on the contrary, they must be taken into account 
as possible useful drugs in the treatment of COVID 19 pa-
tients.
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